Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Sydney Lupkin
Sydney Lupkin was a data correspondent for 麻豆女优 Health News until November 2019.
Showing 21 - 40 of 43
-
-
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
-
Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won鈥檛 be.聽
By Sydney Lupkin and Pauline Bartolone -
Nearly 1 In 3 Recent FDA Drug Approvals Followed By Major Safety Actions
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, 鈥渂lack box鈥 warnings or other actions.
-
Drugmakers Dramatically Boosted Lobbying Spending In Trump鈥檚 First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
-
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump鈥檚 Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump鈥檚 inauguration, which earned them entry into private events with the president and vice president.
-
Repeal & Replace Watch
By The Numbers: Trump’s Choice For FDA Chief Is Versatile, Entrenched In Pharma
The numbers show that President Trump鈥檚 choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
-
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
By Sarah Jane Tribble and Sydney Lupkin -
Making Multiple Drugs In One Factory Risks Scary Side Effect Of Shortages
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
-
The Orphan Drug Machine
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
By Sarah Jane Tribble and Sydney Lupkin -
Repeal & Replace Watch
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
By Sydney Lupkin and Sarah Jane Tribble -
The Orphan Drug Machine
Drugmaker Marathon 鈥楶ausing鈥 Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
By Sarah Jane Tribble and Sydney Lupkin -
Repeal & Replace Watch
Six U.S. Senators Confronting Trump鈥檚 HHS Cabinet Pick Own Health Care Stocks, Too
Donald Trump鈥檚 pick to run HHS has been under fire for trading health care stocks but at least six senators at his confirmation hearings also own such stocks.
-
The Orphan Drug Machine
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
-
The Orphan Drug Machine
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren鈥檛 new or were repurposed multiple times, an investigation shows.
By Sarah Jane Tribble and Sydney Lupkin -
Grab Bag Of Goodies In 21st Century Cures Act
A breakdown of winners 鈥 and a few losers 鈥 in the sprawling Cures Act approved by the House.
By Sydney Lupkin and Steven Findlay -
A Frenzy Of Lobbying On 21st Century Cures
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
-
FDA鈥檚 Drug Approval Team Copes With 700 Unfilled Jobs As Industry Lures Staff
The FDA鈥檚 drug-approval team is short more than 700 people and losing skilled staff members to the drug industry.
By Sydney Lupkin and Sarah Jane Tribble -
Hospitals Say They鈥檙e Being Slammed By Drug Price Hikes
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
-
When Drug Reviewers Leave The FDA, They Often Work For Pharma
Researchers examine the Food and Drug Administration鈥檚 鈥渞evolving door鈥 regarding employees who worked on cancer and hematology drugs.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: